Fludarabine phosphate
Based on 9 publication(s) in Google Scholar
Fludarabine (phosphate) is an analogue of adenosine and deoxyadenosine, which is able to compete with dATP for incorporation into DNA and inhibit DNA synthesis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.77%
- CAS No.: 75607-67-9
- Formule: C10H13FN5O7P
- Masse moléculaire:365.21
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Reprogramming Compound Library
HY-L039
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Pediatric Drug Library
HY-L104
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Non-steroidal Anti-Inflammatory Compound Library
HY-L130
-
Off-patent Drug Library
HY-L141
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Cancer Approved Drug Library
HY-L213
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
Publications Citing Use of MedChemExpress (MCE) Fludarabine phosphate
More- Nat Cancer. 2023 Aug;4(8):1193-1209. [Abstract]
- Nat Metab. 2025 Nov 13. [Abstract]
- Cell Stem Cell. 2026 May 7;33(5):800-819.e9. [Abstract]
- Nat Cell Biol. 2024 Dec;26(12):2168-2182. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- Antiviral Res. 2020 Jun;178:104786. [Abstract]
- Carcinogenesis. 2025 Oct 22:bgaf069. [Abstract]
- bioRxiv. 2025 Mar 13:2025.03.11.642569. [Abstract]
- Research Square Print. 2022 Aug.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
WB
-
Flow Cytometry
-
In Vivo Efficacy Study
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CCRF-CEM | IC50 |
0.4 μM
Compound: 466
|
Anticancer activity against human CCRF-CEM cells
Anticancer activity against human CCRF-CEM cells
|
[PMID: 34213340] |
| HeLa | IC50 |
2 μM
Compound: fludarabine phosphate, F-ara-AMP
|
Antiproliferative activity against human M-HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human M-HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 25960323] |
| HEp-2 | IC50 |
9 μM
Compound: 466
|
Anticancer activity against human HEp-2 cells
Anticancer activity against human HEp-2 cells
|
[PMID: 34213340] |
| HL-60 | IC50 |
0.09 μM
Compound: fludarabine phosphate, F-ara-AMP
|
Antiproliferative activity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 25960323] |
| K562 | IC50 |
0.15 μM
Compound: 466
|
Anticancer activity against human K562 cells
Anticancer activity against human K562 cells
|
[PMID: 34213340] |
| K562 | IC50 |
0.4 μM
Compound: fludarabine phosphate, F-ara-AMP
|
Antiproliferative activity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 25960323] |
| KG-1 | IC50 |
0.15 μM
Compound: fludarabine phosphate, F-ara-AMP
|
Antiproliferative activity against human KG1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human KG1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 25960323] |
| L1210 | IC50 |
3 μM
Compound: 466
|
Anticancer activity against mouse L1210 cells
Anticancer activity against mouse L1210 cells
|
[PMID: 34213340] |
| MCF7 | IC50 |
0.13 μM
Compound: fludarabine phosphate, F-ara-AMP
|
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 25960323] |
| MOLT-3 | IC50 |
0.95 μM
Compound: fludarabine phosphate, F-ara-AMP
|
Antiproliferative activity against human MOLT3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human MOLT3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 25960323] |
| Raji | IC50 |
0.4 μM
Compound: fludarabine phosphate, F-ara-AMP
|
Antiproliferative activity against human Raji cells assessed as cell growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human Raji cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 25960323] |
| Skut1B | IC50 |
6 μM
Compound: fludarabine phosphate, F-ara-AMP
|
Antiproliferative activity against human SK-UT-1B cells assessed as cell growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human SK-UT-1B cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 25960323] |
| ZR-75-1 | IC50 |
0.6 μM
Compound: fludarabine phosphate, F-ara-AMP
|
Antiproliferative activity against human ZR-75-1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human ZR-75-1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 25960323] |
Fludarabine phosphate significantly reduces the cell viability in a dose-dependent manner. Fludarabine phosphate exhibits no effect in all tested concentrations when combined with either PBS or control vector, ACE-GFP. Fludarabine phosphate causes a significant decrease in cell viability for 24 h after exposure to ACE-PNP when compared to PBS and ACE-GFP at concentrations of 2.5, 5 and 10 μg/mL[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 75607-67-9
-
Appearance Solid
-
Masse moléculaire 365.21
-
Formule C10H13FN5O7P
-
Color White to off-white
-
SMILES
NC1=C2C(N([C@H]3[C@@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O3)C=N2)=NC(F)=N1
-
Synonyms
NSC 118218 phosphate
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Nat Cancer
Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms. [Abstract]2023 Aug;4(8):1193-1209. PMID: 37550517 -
Nat Metab
Uridine-sensitized screening identifies demethoxy-coenzyme Q and NUDT5 as regulators of nucleotide synthesis. [Abstract]2025 Nov 13. PMID: 41233602 -
Cell Stem Cell
2026 May 7;33(5):800-819.e9. PMID: 42030946 -
Nat Cell Biol
NAT10-mediated mRNA N4-acetylcytidine reprograms serine metabolism to drive leukaemogenesis and stemness in acute myeloid leukaemia. [Abstract]2024 Dec;26(12):2168-2182. PMID: 39506072
Fludarabine phosphate purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2024 Dec;26(12):2168-2182. [Abstract]
MTT assays and the IC50 values of Remodelin, Fludarabine, fosaprepitant, dantrolene and folinic acid in MOLM13 cells after 72 h of treatment.
Fludarabine phosphate purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2024 Dec;26(12):2168-2182. [Abstract]
Western blotting showing the protein levels of NAT10 targets and downstream genes in MOLM13 cells with Fludarabine or Remodelin treatment.
Fludarabine phosphate purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2024 Dec;26(12):2168-2182. [Abstract]
The proportion of MOLM13 cells at different cell cycle stages after treatment with 20 μM Remodelin or 1 μM Fludarabine for 72 hours. Examples show EdU labeling and PI staining, followed by flow cytometry assessment of the MOLM13 cell cycle.
Fludarabine phosphate purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2024 Dec;26(12):2168-2182. [Abstract]
Body weight of C1498 homologous AML mice after intraperitoneal injection of Fludarabine (200 mg/kg) or corresponding vector control.
-
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
Antiviral Res
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. [Abstract]2020 Jun;178:104786. PMID: 32251767 -
Carcinogenesis
A2AR-phospho-STAT1 (Y701)-HLA-E axis as a potential immune modulatory pathway in radiotherapy-resistant triple negative breast cancer. [Abstract]2025 Oct 22:bgaf069. PMID: 41122851 -
bioRxiv
Uridine-sensitized screening identifies genes and metabolic regulators of nucleotide synthesis. [Abstract]2025 Mar 13:2025.03.11.642569. PMID: 40161720 -
Solvant et solubilité
DMSO : ≥ 100 mg/mL (273.82 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 5 mg/mL (13.69 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: phosphate buffer Saline
Solubility: 20 mg/mL (54.76 mM); Clear solution; Need ultrasonic
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.85 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.85 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 18.33 mg/mL (50.19 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
Briefly, 2×103 KU-19-19 cells are seeded in each well of 96-well plates and allowed to grow overnight. Cells are then exposed to PBS, ACE-GFP or ACE-PNP for 3 h. Twenty-four hours post-infection, the cells are treated with various concentrations of fludarabine phosphate. After the 24-h incubation, cytotoxicity is determined by using WST-1; 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate. The absorbance value is determined at 450 nm by a microplate reader.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice: Parental and E. coli PNP expressing D54MG (human glioma) tumor cells (2×107 cells) are injected subcutaneously into the flanks of nude mice (nu/nu). D54 tumor cells stably transduced with E. coli PNP are prepared as described previously. Tumors are measured with calipers and an estimate of the weight calculated using the equation, (length × width2)/2=mm3, and converted to mg assuming unit density. Unless stated otherwise, therapeutic drugs and the adenoviral vector expressing E. coli PNP (Ad/PNP), or vehicle controls are injected into D54 tumors in 150 μL volumes by 8 separate injections of approximately 20 μL each in an effort to evenly distribute the administered agent. At least 6 mice are studied in each treatment group. Mice are monitored daily and body weights and tumor dimensions collected twice weekly. T-C (tumor growth delay) is determined as the difference in median days to 2 doublings (median days to 600 mg for the D54 and DU145 (human prostate cancer) analysis) between drug-treated and vehicle-treated groups. For the NIH-H322M (human non-small cell lung cancer) study, because of tumor proliferation characteristics, total growth inhibition (TGI) is used as the evaluation point. TGI is equal to the control group mean delta minus the treated group mean delta divided by the control group mean delta, where delta is the change in tumor weight for each animal between day 36 and day 59. The time to the evaluation point for each animal is used as the end point for the student's t-test, Mann-Whitney rank sum test, or a life table analysis in order to statistically compare growth data between treatment groups. All key results are repeated under similar conditions and findings confirmed. Treatments are initiated when tumors are 250 to 300 mg (appr 1-1.5% of total animal weight).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (281 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Sorscher EJ, et al. In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase. Cancer Chemother Pharmacol. 2012 Aug;70(2):321-9. [Content Brief]
[2]. Kikuchi E, et al. Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts. Cancer Gene Th [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.7382 mL | 13.6908 mL | 27.3815 mL | 68.4538 mL |
| 5 mM | 0.5476 mL | 2.7382 mL | 5.4763 mL | 13.6908 mL | |
| 10 mM | 0.2738 mL | 1.3691 mL | 2.7382 mL | 6.8454 mL | |
| DMSO | 15 mM | 0.1825 mL | 0.9127 mL | 1.8254 mL | 4.5636 mL |
| 20 mM | 0.1369 mL | 0.6845 mL | 1.3691 mL | 3.4227 mL | |
| 25 mM | 0.1095 mL | 0.5476 mL | 1.0953 mL | 2.7382 mL | |
| 30 mM | 0.0913 mL | 0.4564 mL | 0.9127 mL | 2.2818 mL | |
| 40 mM | 0.0685 mL | 0.3423 mL | 0.6845 mL | 1.7113 mL | |
| 50 mM | 0.0548 mL | 0.2738 mL | 0.5476 mL | 1.3691 mL | |
| 60 mM | 0.0456 mL | 0.2282 mL | 0.4564 mL | 1.1409 mL | |
| 80 mM | 0.0342 mL | 0.1711 mL | 0.3423 mL | 0.8557 mL | |
| 100 mM | 0.0274 mL | 0.1369 mL | 0.2738 mL | 0.6845 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Fludarabine phosphate Related Classifications
HY-B0028 Related Classifications
Powered by Bioz